SLC22A8 and oral cavity squamous cell carcinoma: TMIGD2 is a related immune checkpoint receptor, and higher levels of TMIGD2 (a related immune checkpoint receptor) The prognosis of patients with oral squamous cell carcinoma tends to be poorer.[45] Upregulation of suppressive immune checkpoint molecules, which can reduce immune cell activity, is a key feature of inflammatory TME.[46] Thus, patients in the SLC22A8 low expression group were in inflammatory TME.